Загрузка...
Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
BACKGROUND: Galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days in phase 2 and 3 trials. In these analyses, we aimed to evaluate the safety and tolerability of galcanezumab...
Сохранить в:
| Опубликовано в: : | BMC Neurol |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6966798/ https://ncbi.nlm.nih.gov/pubmed/31952501 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-020-1609-7 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|